why choose us

First received: May 31, 2023

Clinical Trial: TQB2223 Injection in Combination With Penpulimab in Patients With Advanced Cancers

Study Status: Completed

Recruit Status: RECRUITING

Condition: Advanced Cancer

Study Type: INTERVENTIONAL


Official Title: Phase I Clinical Trial to Evaluate the Tolerability and Pharmacokinetics of TQB2223 Injection Combined With Penpulimab Injection in Subjects With Advanced Cancers

Brief Summary: TQB2223 is a recombinant, fully humanized antibody that binds lymphocyte activation gene-3 (LAG-3) and blocks the LAG-3/ major histocompatibility complex class II (MHC-II) interaction, thus allowing for increased T-cell proliferation and cytokine production.This is a phase I study to evaluate the safety, tolerability, pharmacokinetics (PK) and effectiveness of TQB2223 injection in combination with Penpulimab in subjects with advanced cancers.

Read more